Click here for slides on this topic


apolipoprotein B (apoB)

The B apolipoproteins are the primary apolipoproteins of low-density lipoproteins (LDL) and in lesser amounts in chylomicrons.
The following content matched the glossary term: apolipoprotein B (apoB)

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus

Top

Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10(12):1875-1882. The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients.

Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin

Top

Derosa G, D'Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther. 2009;34(1):13-23. Most antidiabetic agents target only one of several underlying causes of diabetes. The complementary actions of the glinides and the biguanides may give optimal glycemic control in patients with type 2 diabetes mellitus.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

Top

Fruchart JC, Sacks FM, Hermans MP, et al, for the Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-35. Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure and glycaemia, dyslipidaemic patients remain at high residual risk of vascular events.

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

Top

Derosa G, D'Angelo A, Salvadeo SA, et al. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism. 2008;57(11):1552-1557. Thiazolidinediones are supposed to be the pharmacologic agents that more physiologically fight the insulin resistance, but a possible adverse effect may be a weight increase. The aim of the study was to test the efficacy and tolerability of sibutramine on the metabolic effect of pioglitazone in obese patients with type 2 diabetes mellitus.

Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline

Top

Rosenzweig JL, Ferrannini E, Grundy SM. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(10):3671-3689. The objective was to develop clinical practice guidelines for the primary prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in patients at metabolic risk.

Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension

Top

Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, et al. Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension. Diabetes Care. 2003;26:2588-2594. The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes. Insulin resistance may occur frequently in nondiabetic patients with hypertension.

Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

Top

Füllert S, Schneider F, Haak E, et al. Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study. J Clin Endocrinol Metab. 2002;87:5503-5506. Hypertension is often associated with insulin resistance, dyslipidemia and obesity, which indicate a prediabetic state and increased risk of cardiovascular disease. Pioglitazone treatment of patients with type 2 diabetes reduces insulin resistance and improves lipid profiles.

Apolipoprotein E Kinetics: Influence of Insulin Resistance and Type 2 Diabetes

Top

Bach-Ngohou K, Ouguerram K, Nazih H, et al. Apolipoprotein E Kinetics: Influence of Insulin Resistance and Type 2 Diabetes. Int J Obesity. 2002;26:1451-1458. The aim of this study was to explore apoE kinetics of obese subjects and to determine what parameters could influence its metabolism.

1 2 3 Next 

Slide Library Results

Search Results for: apolipoprotein B (apoB) Slides Found: 1
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis